Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02051101 · ClinicalTrials.gov registry record · NA
Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples
A NA study, sponsored by University of California, Irvine.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02051101: Completed NA study, sponsored by University of California, Irvine.
NCT02051101 is a NA study that has completed, run by University of California, Irvine. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02051101, a NA study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the pathogenic mechanisms of Port Wine Stain, collect biopsy samples and blood samples to characterize exosomes and metabolites from Port Wine Stain.
Interventions
- OTHER Biopsy sample from Port Wine Stain Birthmark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-04-23 |
| Est. Completion | 2019-01-11 |
| Phase | NA |
What the finished NCT02051101 record still lists
NCT02051101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Biopsy sample from Port Wine Stain Birthmark is the first listed.
NCT02051101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02051101 about?
NCT02051101 is a clinical study titled "Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples". The purpose of this study is to investigate the pathogenic mechanisms of Port Wine Stain, collect biopsy samples and blood samples to characterize exosomes and metabolites from Port Wine Stain.
What is the current status of trial NCT02051101?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2013-04-23. Estimated completion is 2019-01-11.
What interventions are being tested in trial NCT02051101?
The interventions under investigation include: Biopsy sample from Port Wine Stain Birthmark (OTHER).
Who is sponsoring clinical trial NCT02051101?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02051101's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI